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A B S T R A C T
Purpose: Histamine H3 receptor ligands may have antidepressant and anxiolytic effects. They can also com-
pensate for metabolic disorders, which affect glucose or triglyceride levels. In previous studies, we have shown
that pitolisant, a histamine H3 receptor antagonist/inverse agonist and σ1 receptor agonist, prevented the de-
velopment of certain metabolic and depressive-like disorders in mice that have been treated chronically with
olanzapine.
Methods: As a continuation of our previous experiments, this study aimed to investigate the antidepressant- and
anxiolytic-like activity of pitolisant in mice using the corticosterone-induced depression model. The forced swim
and the elevated plus maze tests were used as behavioral endpoints. We also studied the effect pitolisant had on
the level of acetoacetic acid in the urine as well as the glucose tolerance and body weight of the mice that had
been administered corticosterone.
Results: Pitolisant (10mg/kg b.w.) did not prevent depressive-like behavior in mice during the chronic corti-
costerone administration but did counteract anxiety-like behavior, whilst fluoxetine (10mg/kg) was shown to
protect the mice from both of these behaviors. None of the treatments that were used in the study showed an
effect on the locomotor activity of the mice. Pitolisant did not prevent an increase in acetoacetic acid levels in the
urine, nor did it improve glucose tolerance in the tested mice.
Conclusion: Although literature data indicates that there is significant potential for finding an antidepressant and
anti-diabetic drug among the histamine H3 and σ1 receptor ligands, in our study, pitolisant was shown to only
slightly compensate for corticosterone-induced abnormalities. However, further research will be required to
study pitolisant's anxiolytic-like activity.
1. Introduction
Endogenous glucocorticoids are naturally occurring stress hormones
that are secreted by the adrenal glands (Wong et al., 2016). As a re-
sponse to stress, the hypothalamic–pituitary–adrenal axis (HPA axis) is
activated, resulting in a cascade of neuroendocrine biochemical events.
This cascade includes the release of corticotropin-releasing factor (CRF)
from the hypothalamus, which, in turn, causes the release of adreno-
corticotropin hormone (ACTH) from the anterior pituitary. This ulti-
mately results in the secretion of glucocorticoids from the adrenal
glands into the circulatory system (in the form of cortisol in humans
and corticosterone in rodents). Under normal conditions, the blood
glucocorticoid level is tightly regulated by a negative feedback me-
chanism (Gong et al., 2016).
Depression and anxiety occur in over 50% of patients with Cushing's
syndrome (Dimopoulou et al., 2013) and up to 20% of patients who
receive exogenous glucocorticoids for immunosuppressive therapy
(Kenna et al., 2011). Chronic glucocorticoid administration also pro-
motes depressive-like and anxiety-like behaviors in animals (Sterner
and Kalynchuk, 2010). Various compounds with antidepressant-like
activity have been shown to significantly reverse the behavioral
changes which are induced by corticosterone administration (Crupi
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et al., 2010; Huang et al., 2011; Mao et al., 2012).
Glucocorticoids also cause metabolic disturbances by acting directly
on different tissues, e.g.: fat, liver, and kidneys. They promote gluco-
neogenesis in the liver and can cause hyperglycemia, insulin resistance
and glucose intolerance; they can also stimulate the differentiation of
pre-adipocytes into mature adipocytes, which increases lipolysis, in
turn releasing free fatty acids (Ferris and Kahn, 2012; Fransson et al.,
2013). Both endogenous and exogenous glucocorticoids have been used
to induce metabolic syndrome in animal models (Wong et al., 2016).
Antidepressant drugs can enhance glucocorticoid receptor-mediated
inhibition of the HPA axis by increasing the expression of the gluco-
corticoid receptor (GR), this leads to a decrease in the level of cortisol/
corticosterone (Budziszewska, 2002). Sigma-1 receptor (σ1R) defi-
ciency causes down-regulation of the GR by reducing protein kinase C
phosphorylation; this attenuates the GR-mediated feedback inhibition
of the HPA axis and facilitates the stress response of the HPA axis,
leading to the production of depressive-like behaviors (Di et al., 2017).
σ1R is highly expressed in regions of the brain that are involved in
emotion and neuropsychiatric disorders (Hayashi and Su, 2004), and
σ1R agonists are a class of drugs used for the treatment of depression
(Urani et al., 2001) and anxiety (Longone et al., 2011). The anti-
depressant-like activity of σ1R ligands can be directly connected with
the GR function (Skuza et al., 2008). Furthermore, σ1R agonists en-
hance the functionality of the N-methyl-D-aspartate (NMDA) receptor,
which controls various neuronal functions, including synaptic plasticity
(Su et al., 2016), they can also increase dopaminergic neurotransmis-
sion in certain brain areas (Garcés-Ramírez et al., 2011). Activation of
this receptor could also mitigate reactive oxygen species accumulation,
possibly through the modulation of reactive oxygen species-neu-
tralizing proteins (Nguyen et al., 2015). The properties mentioned
above may be associated with the beneficial effects of σ1R agonists on
behavioral disorders; therefore, stimulation of σ1R appears to be a good
starting point in the search for new antidepressant drugs. Some studies
demonstrate that σ1R agonists can modulate the activities of neuro-
transmitter systems, signaling pathways, and the brain regions im-
plicated in the pathophysiology of depression (Fishback et al., 2010).
σ1R agonists have also been shown to decrease the immobility time in
both the tail suspension test and the forced swim test in mice (Ukai
et al., 1998; Urani et al., 2001; Skuza and Rogóż, 2002).
Histamine plays a significant modulatory role in starting the neu-
roendocrine response to stress, for example, the release of several pi-
tuitary hormones such as ACTH (Kjaer et al., 1992). The histamine H3
receptor (H3R) was identified pharmacologically as a presynaptic au-
toreceptor, which regulates the release of histamine from histaminergic
neurons (Arrang et al., 1983). The released histamine decreases the
further release of histamine, by affecting the presynaptic H3 auto- or
heteroreceptor and also inhibits the release of various other neuro-
transmitters (Singh and Jadhav, 2013). Several studies have demon-
strated that activation or inactivation of the histamine receptors appear
to exert a modulatory role in the regulation of the blood glucose level
(Sim et al., 2014). H3R may regulate glucose levels directly through the
release of insulin (Henry et al., 2011). This receptor is expressed in
mouse beta cells (Nakamura et al., 2014) and is a potential target for
the pharmacological treatment of glucose intolerance or diabetes
(Henry et al., 2011).
Pitolisant is one of two currently available drugs (the other being
betahistine) that works by acting on H3R - an antagonist
(Ki= 1.0–2.4 nM)/inverse agonist (EC50= 1.5 nM) (European
Medicines Agency, 2015). Pitolisant was not specific for H3R over σ1R
and σ2 receptors (σ2R). Pitolisant binds to the human σ1R with a
subnanomolar Ki (Ki= 0.5 nM). It shows functional activity on σ1R-
mediated calcium flux, demonstrating agonism with an EC50 of 402 nM.
The in vitro assays showed that pitolisant binds to σ2R with a Ki of
6.5 nM and an IC50 of 8.55 nM. In a σ2R-mediated calcium flux func-
tional assay, pitolisant did not elicit agonist activity but behaved as an
antagonist since it decreased haloperidol-induced calcium release with
an IC50 of 10 μM (European Medicines Agency, 2015). In our previous
studies, we have shown that this drug may reduce depressive-like and
metabolic disorders induced by the repeated administration of olanza-
pine (Dudek et al., 2016). Repeated administration of pitolisant has also
been shown to improve glucose tolerance in obese mice (Kotańska
et al., 2018). In this study, we aimed to examine whether pitolisant
could reduce the behavioral and/or metabolic disorders caused by
chronic corticosterone administration in mice.
2. Materials and methods
2.1. Animals
Adult male mice (CD-1, 18–21 g) were used for this experiment. The
animals were purchased from the Animal House at the Faculty of
Pharmacy, Jagiellonian University Medical College, Krakow, Poland.
The mice were housed in a plastic cage maintained at room temperature
(22 ± 2 °C), on a 12 h light/dark cycle (the lights came on at 7:00 a.m.
and went off at 7:00 p.m.). During the habituation period, all mice had
free access to their standard laboratory pellets and tap water. All be-
havioral procedures were performed between 9 a.m. and 2 p.m. Each
experimental group consisted of 8 animals that had been randomly
selected. After the experiment, the mice were killed by cervical dis-
location. All experimental procedures were carried out under EU
Directive 2010/63/EU and approved by the Local Ethics Committee for
Experiments on Animals at the Jagiellonian University in Krakow,
Poland (approval number: 45/2017).
2.2. Drugs
Pitolisant was synthesized in the Department of Technology and
Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University
Medical College, Krakow, Poland. Pitolisant or fluoxetine (Sigma,
Germany) were dissolved in 1% Tween 80 and administered in-
traperitoneally (i.p.) at a volume of 10ml/kg. The doses of pitolisant
(10mg/kg b.w./day) and fluoxetine (10mg/kg b.w./day) were chosen
based on previous experiments carried out in our laboratory (Dudek
et al., 2016; Pytka et al., 2015). Corticosterone (Sigma, Germany) was
dissolved in 1% dimethylsulfoxide (DMSO) and administered sub-
cutaneously at a dose of 20mg/kg b.w./day, at a volume of 10ml/kg.
2.3. Experimental design
Mice were subjected to the chronic stress-like procedure by the
subcutaneous administration of corticosterone suspended in 0.1%
DMSO at a dose of 20mg/kg for 21 days (Fig. 1) (Pytka et al., 2018).
These mice received an additional intraperitoneal injection of 1%
Tween 80 (the vehicle of the compounds). The control group was
subcutaneously injected with the corticosterone's vehicle, composed of
0.1% DMSO; they were also administered 1% Tween 80 i.p. Simulta-
neously, certain groups of mice received corticosterone subcutaneously
and pitolisant (10mg/kg/day) or fluoxetine (10mg/kg/day) i.p. Fur-
thermore, some mice received only pitolisant (10mg/kg/day) chroni-
cally. On the 20th day, animals were placed into metabolic cages for
24 h in order to collect their urine. On consecutive days, we conducted
the locomotor activity test (LA), FST, elevated plus maze test (EPM) and
finally, the glucose tolerance test (GTT) – which was carried out after
removing the diet for 20 h. Urine collection and the locomotor activity
test were carried out prior to the next administration of corticosterone
and the studied drugs.
2.4. Locomotor activity
The locomotor activity test was performed as previously described
(Pytkaa et al., 2016). Briefly, locomotor activity was recorded in-
dividually for each animal using specially designed activity cages which
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were made from clear Perspex (40 cm×40 cm×31 cm, Activity Cage
7441, Ugo Basile, Italy). The cages came supplied with infrared (I.R.)
horizontal beam emitters connected to a counter which recorded the
light-beam interruptions. Each mouse was placed in a cage for a 30-
minute habituation period. After that time, the number of breaks in the
photobeams was measured for 6min. For analysis, we used the time
slots from the 1st to the 5th min and from the 2nd to the 6th min, which
corresponded with the observation periods used in the elevated plus
maze and forced swim test, respectively. The cages were disinfected
with 70% ethanol after use by each mouse.
2.5. Forced swim test
The forced swim test was performed according to the method which
we previously described (Pytkab et al., 2016). Mice were placed in-
dividually into a glass cylinder (height 25 cm, diameter 10 cm) con-
taining water (23–25 °C) at a depth of 10 cm for 6min. After a two-
minute habituation period, the immobility time was recorded for the
next 4min. The experiments were recorded and scored using the
aLab.io software operated by a trained observer who was blind to the
treatments.
2.6. Elevated plus maze
The elevated plus maze was performed according to the method
described by Sałat et al. (2015). The elevated plus maze used was
specifically designed for mice, it consisted of two opposing open arms
(30 cm×5 cm) and two opposing enclosed arms
(30 cm×5 cm×25 cm), which were connected by a central platform
that formed the shape of a plus sign (+). The open and closed arms
were connected with a central field (5 cm×5 cm). Each mouse was
individually placed in the central field of the apparatus with the head
pointing toward one of the closed arms. The animals' behavior was then
observed for 5min. The device was disinfected with 70% ethanol after
each mouse completed the test. The number of entries into the open and
closed arms and the time spent in these open and closed arms were
recorded. The experiments were again recorded and scored using the
aLab.io software operated by a trained observer who was blind to the
treatments.
2.7. Glucose tolerance test
This test was performed on the 25th day of the experiment. After
which each mouse had been administered twenty-one doses of the test
compound. Food was removed for 20 h prior to the glucose tolerance of
the mice being tested. Glucose (1 g/kg b.w.) was administered i.p.
(Kotańska et al., 2018; Kotańska et al., 2019). Blood samples were taken
from the tail vein at several time points, the first of which started prior
to glucose administration (0min) and then samples were taken at 30-
minute intervals after administration, up until the 120-minute time
point (30-, 60-, 90-, and 120-minute time points). Glucose levels were
measured with a glucometer (ContourTS, Bayer, Germany, test stripes:
ContourTS, Ascensia Diabetes care Poland Sp. z o.o., Poland, REF:
84239666).
2.8. Urine collection and determination of ketone bodies
This test was performed on the 20th day of the experiment after
twenty administrations of the test compound. Animals were sub-
cutaneously administered 2ml of 0.9% saline and placed into the me-
tabolic cage. Urine was collected for 24 h. Some ketone bodies such as
acetoacetic acid were produced during disturbed carbohydrate and fat
metabolism and were labeled with stripes (Keto-Diastix REF 2883,
Bayer).
2.9. Body weight changes
Mouse body weight was measured every day throughout the chronic
procedure (before the administration of compounds) using specially
designed scales (WPT 1c, RADWAG).
2.10. Data analysis
Results are presented as means± SEM. With exception of the results
from the body weight changes and the GTT, all other comparisons be-
tween experimental and control groups were performed by one-way
ANOVA, followed by Newman-Keuls post hoc (GraphPad Prism Version
6.00 software). The body weight changes and GTT were assessed using
two-way ANOVA with repeated measures, followed by Bonferroni post
hoc. A value of p < 0.05 was considered to be significant.
3. Results
3.1. Pitolisant's influence on depressive-like behavior in corticosterone-
treated mice
Chronic administration of corticosterone increased the immobility
in the test compound group of mice by 15.9% when compared to the
non-corticosterone-treated control groups (Fig. 2A). Pitolisant (10mg/
kg/day) co-administered for 21 days did not prevent the increase in
immobility induced by corticosterone. However, the administration of
fluoxetine did prevent the negative behavioral changes, i.e., the re-
ference drug decreased the immobility time by 25.7% as opposed to the
corticosterone-treated control mice (F(3,26)= 16.320, p < 0.001).
Pitolisant did not show any influence on the measured parameter (data
not shown).
Fig. 1. Scheme of experiment.
EPM – elevated plus maze, FST – forced swim test, GTT – glucose tolerance test, LA – locomotor activity.
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3.2. Pitolisant's influence on locomotor activity of the corticosterone-treated
mice
There were no significant changes in locomotor activity between the
non-corticosterone- and corticosterone- treated groups (Fig. 2B). When
administered for 20 days, neither pitolisant (at the dose 10mg/kg) nor
fluoxetine (at the dose 10mg/kg) showed an influence on locomotor
activity during a 4-minute session in the corticosterone-treated mice (F
(3,26)= 1.051, p=0.387).
3.3. Pitolisant's influence on anxiety-like behavior in corticosterone-treated
mice
Corticosterone treatment caused a decrease in the number of open
arm entries (Fig. 2C) and the time spent in the open arms (Fig. 2D) by
47% and 39.9%, respectively. Both fluoxetine (10mg/kg/day) and pi-
tolisant (10mg/kg/day), administered for 23 days, reversed these ne-
gative changes by increasing the time spent in the open arms by 57.8%
and 64.2% (F(3,26)= 3.521, p < 0.05) respectively and increased the
open arm entries by 64.5% and 89.8% (F(3,26)= 4.025, p < 0.05),
respectively.
3.4. Pitolisant's influence on glucose tolerance
Fasting glucose concentrations were measured after 20 h of food
deprivation and prior to the glucose load test. Blood glucose levels of
both groups treated with corticosterone (corticosterone alone and pi-
tolisant + corticosterone) did not differ significantly at the same time
points and only at the 120minute time point (after glucose load) was it
significantly higher than when compared with the glucose level of the
control mice. In the group treated with only pitolisant (without corti-
costerone), we observed a significantly lower glucose level compared
with the control mice (treated with 1% Tween) at the 90min after
glucose loading time point. However, 120min after glucose loading, the
glucose level normalised and did not differ significantly between the
groups treated with either only pitolisant or only 1% Tween 80. At
these two time points, glucose levels in both the groups which received
pitolisant were significantly different. Therefore, pitolisant did not
prevent higher glucose levels 120min after glucose loading in the
corticosterone-treated mice. Pitolisant alone however, had a positive
effect on the post-load glucose level. Fig. 3A shows these results.
Fig. 2. Effect of pitolisant and fluoxetine on the behavior of mice chronically treated with corticosterone.
A. Forced swim test. B. Locomotor activity. C, D. Elevated plus maze test. Statistical analysis: one-way ANOVA (Newman-Keuls post hoc); *p < 0.05 vs control
(vehicle + vehicle); #p < 0.05, ###p < 0.001 vs corticosterone control (vehicle + corticosterone); mean ± SEM, n= 8.
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3.5. Pitolisant's influence on corticosterone-induced disturbed combustion of
energy material (level of urine acetoacetic acid – some ketones bodies)
In both groups treated with corticosterone (corticosterone alone and
pitolisant + corticosterone), acetoacetic acid was found in the urine.
This result confirms that corticosterone disrupts energy metabolism and
shows that, unfortunately, pitolisant is not able to reverse this effect
when it is administered for 20 days. The results can be seen in Fig. 3B.
3.6. Influence of pitolisant on body weight changes in mice treated with
corticosterone
Fig. 4A shows the effects seen on the body weight of the mice on
individual days of the experiment. The body weight was significantly
reduced by 50% in the first week, 33% in the second and 50% in the
third week in the group of mice that were chronically treated with
corticosterone and receiving 1% Tween 80 compared with the non-
corticosterone-treated controls (Fig. 4B). Body weights in the groups
treated with pitolisant together with corticosterone (both given at a
dose of 10mg/kg b.w./day), were only reduced by 12.5% in the first
week of administration, then by 33% in the second week and by 75% in
the third week. Interestingly, in the mice from the group treated with
pitolisant plus corticosterone, it was only during the third week that
body weight was significantly lower than in the control group. Weight
loss in this group was also lower than in the corticosterone group.
4. Discussion
In our study, in order to examine whether pitolisant can, at least in
part, prevent the occurrence of the central nervous system and meta-
bolic disorders induced by chronic corticosterone administration, we
assessed the effect of the parallel administration of both drugs on the
animals' behavior (i.e., depression- or anxiety-like behaviors) and the
metabolic changes seen (i.e., glucose intolerance, ketone bodies in
urine, body weight change). Considering that glucocorticosteroids are
often used for the treatment of autoimmune, inflammatory and allergic
diseases and that their chronic use causes many unacceptable side ef-
fects, including obesity, diabetes or panic, anxiety and depression dis-
orders (Ceccarelli et al., 2018; Poznańska et al., 2019; Sullivan et al.,
2018; Sakimura et al., 2018; Wichmann et al., 2017; Fischer et al.,
2018), the search for a therapeutic solution for this problem is critical
from both a social and an economic point of view.
Earlier studies using mice have also shown that pitolisant shows an
antidepressant-like effect in the tail suspension test at a dose of 10mg/
kg, i.p., which may be associated with the effect of this drug on σ1R
(Ki= 0.5 nM) (European Medicines Agency, 2015). Besides, when the
drug was administered jointly with olanzapine for 14 days, it sig-
nificantly prevented the development of depressive-like behaviors as
well as some metabolic disorders which were induced by this atypical
antipsychotic in mice (Dudek et al., 2016). In the present study, pito-
lisant was unable to prevent the development of corticosterone-induced
depressive-like behaviors, however, it did show an anxiolytic-like ef-
fect. Therefore, we plan to conduct further research into this area.
In our study, we chose a model in which the induction of depressive-
like and anxiety-like behaviors occurred within three weeks of corti-
costerone administration. During this time, the first metabolic disorders
develop, i.e., reduced glucose tolerance and weight change (Shibata
et al., 2015; Sawamoto et al., 2016), as well as ketone bodies being
present in the urine. Accordingly, we observed similar disorders in our
research. We assumed that pitolisant, as a ligand for the H3R and σ
receptors, could not only compensate for some behavioral disorders but
also contribute to reducing the development of metabolic disorders in
the tested mice. Finally, in the initial period of administration, when
using the two drugs together, the weight changes of the mice were si-
milar to the control group, which would indicate that the induction of
metabolic disorders in these animals was at least partially inhibited.
However, after the first week, the mice treated with pitolisant and
corticosterone began to gain less weight and developed metabolic dis-
orders similar to the group that received only corticosterone; this was
indicated by the presence of ketone bodies and the similar influence
that was seen on the glucose tolerance of these mice.
On the other hand, one of the limitations of this study is that after
this experiment, one cannot conclude if pitolisant just has an anxiolytic-
like effect or attenuated the corticosterone's effect. It is essential to see
in the future if pitolisant has an effect on naive mice. The second lim-
itation is that pitolisant and corticosterone were administered for only
21 days. More prolonged administration could show whether weight
reduction in the group treated with pitolisant together with corticos-
terone is increasing and if it becomes significant enough to take into
account the effectiveness of the metabolic disorders reduction. In the
Fig. 3. Effect of pitolisant on glucose tolerance or level of urine acetoacetic acid in mice under chronic administration of corticosterone.
A. Glucose level curve over time (GTT test), B. Urine acetoacetic acid.
Statistical analysis: two-way ANOVA (Bonferroni post hoc) (A) or one-way ANOVA (Dunnett post hoc) (B); *p < 0.05, ***p < 0.001 corticosterone control (vehicle
+ corticosterone) vs control (vehicle + vehicle); ^p < 0.05, ^^^p < 0.001 pitolisant (pitolisant + corticosterone) vs corticosterone control (vehicle + corticos-
terone); $$$p < 0.001 pitolisant (pitolisant + vehicle) vs control (vehicle + vehicle); &&&p < 0.001 pitolisant (pitolisant + vehicle) vs corticosterone control
(vehicle + corticosterone); mean ± SEM, n= 8.
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rodent model of metabolic disorders which are caused by the admin-
istration of corticosterone, after the initial weight loss (which is asso-
ciated with the development of insulin intolerance and metabolic dis-
orders) the weight of the animals significantly increase in the fifth and
subsequent weeks (after glucose intolerance starts and with the ap-
pearance of insulin resistance) showing corticosterone-induced obesity
is developing (Matsumura et al., 2019). It would be interesting to in-
vestigate what effect a more extended administration of the pitolisant
and corticosterone combination has on the metabolic disorders that
develop during longer corticosterone administration. This would allow
us to evaluate if pitolisant can compensate for certain metabolic dis-
orders (Dudek et al., 2016; Kotańska et al., 2018). The experiments
described in this article should be considered preliminary research.
5. Conclusion
The data gathered in this study suggests that pitolisant possess an-
xiolytic-like activity, although further and more comprehensive studies
need to be undertaken to prove the accuracy of this statement fully.
Therefore, the use of pitolisant to reduce specific side effects of chronic
glucocorticoid administration appears to have potential but will require
more research.
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